Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions

Herman Nilsson-Ehle, Gunnar Birgegård, Jan Samuelsson, Petar Antunovic, Jan Astermark, Hege Garelius, Lena M Engström, Lars Kjeldsen, Lars Ola Nilsson, Anna Olsson, Mette Skov-Holm, Jonas Wallvik, Nina Gulbrandsen, Eva Hellström-Lindberg

    60 Citationer (Scopus)

    Abstract

    Anaemia in low-risk myelodysplastic syndromes (MDS) is associated with reduced quality of life (QoL). Response to treatment with erythropoietin ± granulocyte colony-stimulating factor (G-CSF) is associated with improved QoL, but whether transfusion therapy with higher haemoglobin (Hb) target levels has similar effects is unknown. The objective for this prospective phase II Nordic multicentre trial was to assess QoL, response rate and physical function in elderly anaemic MDS patients treated to a target Hb level of >120 g/L.
    OriginalsprogEngelsk
    TidsskriftEuropean Journal of Haematology
    Vol/bind87
    Udgave nummer3
    Sider (fra-til)244-52
    Antal sider9
    ISSN0902-4441
    DOI
    StatusUdgivet - 2011

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions'. Sammen danner de et unikt fingeraftryk.

    Citationsformater